PAI Holdings, LLC. dba Pharmaceutical Associates Inc
PAI Holdings, LLC. dba Pharmaceutical Associates Inc appears in FDA public data with 7 recalls, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0222-2025, Class III) was initiated on January 7, 2025.
Summary
- Total Recalls
- 7
- 510(k) Clearances
- 0
- Inspections
- 0
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0222-2025 | Class III | Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles | January 7, 2025 |
| D-0722-2021 | Class II | Cimetidine Hydrochloride Oral Solution 300 mg/5 mL, 8 fl oz (237 mL) Rx ONLY, Pharmaceutical Associ | July 29, 2021 |
| D-0723-2021 | Class II | Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, | July 29, 2021 |
| D-0721-2021 | Class II | Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in | July 29, 2021 |
| D-0015-2021 | Class III | Citalopram Oral Solution, USP 20 mg/10 mL, 10 mL unit dose cups, Rx Only, Mfg for: Pharmaceutical As | September 9, 2020 |
| D-1494-2020 | Class II | Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), R | August 4, 2020 |
| D-1060-2020 | Class II | Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bot | March 19, 2020 |